首页 › 基金 › Delaney Capital Management Ltd. › EPRX
Delaney Capital Management Ltd. 对 EPRX 的持仓历史
Eupraxia Pharmaceuticals Inc · 医疗保健
Delaney Capital Management Ltd. 在 Q3 2026 的 13F 申报中披露持有 EPRX(Eupraxia Pharmaceuticals Inc)112,400 股,市值约 US$1.0M,约占其申报组合的 0.16%,在其申报持仓中市值排名第 32 位。 Delaney Capital Management Ltd. 最近 4 个申报季度中有 4 个季度披露了 EPRX 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Delaney Capital Management Ltd. 对 EPRX 的持仓演变
Delaney Capital Management Ltd. 于 Q4 2025 首次披露 EPRX 持仓:119,400 股(约 US$899K)。 该持仓在 Q3 2026 达到峰值 112,400 股,市值约 US$1.0M。 在 4 次申报中,Delaney Capital Management Ltd. 0 次增持、2 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 112,400 股、市值约 US$1.0M,环比减持 -4,800 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 119.40K | $899.03K | 新进 |
| Q1 2026 | 119.40K | $860.02K | 持有 |
| Q2 2026 | 117.20K | $767.86K | 减持 |
| Q3 2026 | 112.40K | $1.03M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 EPRX 与 13F 数据
EPRX(Eupraxia Pharmaceuticals Inc)属于医疗保健行业。我们追踪的基金中还有 70 只申报持有 EPRX,申报仓位最大的包括:Vivo Capital, LLC (US$12.3M), PFM Health Sciences, LP (US$8.0M), GREAT POINT PARTNERS LLC (US$7.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 EPRX 的基金
- Vivo Capital, LLC 1.35M 股 · $12.29M · Q3 2026
- PFM Health Sciences, LP 1.21M 股 · $8.00M · Q2 2026
- GREAT POINT PARTNERS LLC 1.20M 股 · $7.93M · Q2 2026
- Ikarian Capital, LLC 809.74K 股 · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K 股 · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K 股 · $4.04M · Q2 2026
- Aisling Capital Management LP 325.00K 股 · $2.96M · Q3 2026
- Velan Capital Investment Management LP 352.00K 股 · $2.33M · Q2 2026
- Ally Bridge Group (NY) LLC 252.18K 股 · $1.67M · Q2 2026
- Lynx1 Capital Management LP 10.00K 股 · $66.10K · Q2 2026
更多关于 Delaney Capital Management Ltd.
常见问题
How long has Delaney Capital Management Ltd. held EPRX?
Delaney Capital Management Ltd. has disclosed EPRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Delaney Capital Management Ltd.'s current position in EPRX?
As of Q3 2026, Delaney Capital Management Ltd. holds 112.40K shares of EPRX (Eupraxia Pharmaceuticals Inc), valued at $1.03M, representing 0.16% of its reported portfolio and ranking #32.
Has Delaney Capital Management Ltd. been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Delaney Capital Management Ltd. reduced its position in EPRX. The position peaked in Q3 2026 at 112.40K shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Vivo Capital, LLC, PFM Health Sciences, LP, GREAT POINT PARTNERS LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.